IDEXX’s 2025 Corporate Responsibility Report highlights new advances in veterinary diagnostics, workforce development and sustainability initiatives. The report details progress toward the company’s long-term goals while showcasing investments designed to expand access to care, strengthen veterinary practices and support future innovation.
IDEXX Laboratories has expanded its Fecal Dx™ antigen testing platform to include taeniid tapeworm detection, broadening intestinal parasite screening capabilities for veterinarians in routine wellness and sick-pet care.
IDEXX Laboratories is integrating SDMA kidney biomarker testing into its most commonly used Catalyst chemistry profiles, a move designed to help veterinarians identify declining kidney function earlier during routine in-clinic diagnostics.
IDEXX Laboratories reported strong first-quarter growth driven by diagnostics demand and innovation, while increasing its full-year 2026 financial outlook.
IDEXX Laboratories reported strong fourth-quarter and full-year 2025 results driven by sustained growth in companion animal diagnostics, record instrument placements, and operating margin expansion, while providing a confident outlook for continued growth in 2026.
Michael Erickson, PhD, will take over as President and CEO of IDEXX Laboratories in May 2026, succeeding Jay Mazelsky, who will transition to Executive Chair before retiring in 2027.
Sign up for free to receive the latest veterinary news, product announcements, and industry developments.